Annual Report 2020

NOTESTOTHE CONSOLIDATED FINANCIAL STATEMENTS For the year ended 31 December 2020 81 The United Laboratories International Holdings Limited Annual Report 2020 5. REVENUE AND SEGMENT INFORMATION (Continued) Segment information HKFRS 8 Operating Segments requires operating segments to be identified on the basis of internal reports about components of the Group that are regularly reviewed by the chief operating decision maker (“CODM”) (i.e. executive directors of the Company) for the purpose of allocating resources to segments and assessing their performance. The three revenue streams are the operating and reportable segments of the Group on which the Group reports its primary segment information. (a) Segment revenue and results Year ended 31 December 2020 Intermediate Bulk Finished Segment products medicine products total Elimination Consolidated RMB’000 RMB’000 RMB’000 RMB’000 RMB’000 RMB’000 REVENUE External sales 1,429,690 3,620,720 3,722,078 8,772,488 – 8,772,488 Inter-segment sales 1,397,230 592,085 – 1,989,315 (1,989,315) – Segment revenue 2,826,920 4,212,805 3,722,078 10,761,803 (1,989,315) 8,772,488 RESULTS Segment profit 258,072 212,015 886,608 1,356,695 Unallocated other income 193,232 Unallocated corporate expenses (180,078) Unallocated other gains and losses, net 8,372 Loss on fair value change of embedded derivative components of convertible bonds (314,614) Finance costs (181,273) Profit before taxation 882,334